Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients

被引：0
|
作者：
Marit A. C. Vermunt
Merel van Nuland
Lisa T. van der Heijden
Hilde Rosing
Jos. H. Beijnen
Andries M. Bergman
机构：
[1] The Netherlands Cancer Institute,Department of Pharmacy and Pharmacology
[2] The Netherlands Cancer Institute,Department of Medical Oncology
[3] Utrecht University,Department of Pharmaceutical Sciences
[4] Modra Pharmaceuticals B.V.,Department of Oncogenomics
[5] The Netherlands Cancer Institute,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2022年 / 89卷
关键词：
Docetaxel; Pharmacokinetics; Metastatic castration-resistant prostate cancer; Metastatic hormone-sensitive prostate cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：785 / 793
页数：8
相关论文
共 50 条
  • [31] Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
    Talwar, Harkirat Singh
    INDIAN JOURNAL OF UROLOGY, 2021, 37 (03) : 288 - 290
  • [32] Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer
    Saad, Fred
    Fizazi, Karim
    UROLOGY, 2015, 86 (05) : 852 - 861
  • [33] Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting
    Gebrael, Georges
    Chehade, Chadi Hage
    Sayegh, Nicolas
    Tripathi, Nishita
    Chigarira, Beverly
    Goel, Divyam
    Nordblad, Blake
    McFarland, Taylor R.
    Narang, Arshit
    Srivastava, Ayana
    Tandar, Clara
    Dal, Emre
    Jo, Yeonjung
    Fortuna, Gliceida Galarza
    Thomas, Vinay Mathew
    Sahu, Kamal K.
    Li, Haoran
    Maughan, Benjamin L.
    Swami, Umang
    Agarwal, Neeraj
    PROSTATE, 2024, 84 (09): : 888 - 892
  • [34] Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer
    Kwan, Edmond M.
    Fettke, Heidi
    Crumbaker, Megan
    Docanto, Maria M.
    To, Sarah Q.
    Bukczynska, Patricia
    Mant, Andrew
    Ng, Nicole
    Foroughi, Siavash
    Graham, Lisa-Jane K.
    Haynes, Anne-Maree
    Azer, Sarah
    Lim, Lisi Elizabeth
    Segelov, Eva
    Mahon, Kate
    Davis, Ian D.
    Parente, Phillip
    Pezaro, Carmel
    Todenhofer, Tilman
    Sathianathen, Niranjan
    Hauser, Christine
    Horvath, Lisa G.
    Joshua, Anthony M.
    Azad, Arun A.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2021, 10 (04)
  • [35] Determination of direct treatment costs of patients with metastatic and nonmetastatic castration-resistant (mCRPC, nmCRPC) and metastatic hormone-sensitive (mHSPC) prostate cancer in Colombia.
    Nino, Rafael
    Restrepo-Miranda, Diego
    Amezquita, Miguel Alberto
    Lancheros, Jeisson
    Corredor, Lina Maria
    Medina, Yudy
    Aguirre, Andres
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18838 - E18838
  • [36] Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel
    Sonpavde, Guru
    Pond, Gregory R.
    Templeton, Arnoud J.
    Fandi, Abderrahim
    Tombal, Bertrand
    Rosenthal, Mark
    Armstrong, Andrew J.
    Petrylak, Daniel P.
    EUROPEAN UROLOGY, 2016, 69 (06) : 980 - 983
  • [37] Indirect comparison of abiraterone acetate and docetaxel for treatment of metastatic "hormone-sensitive" prostate cancer
    Feyerabend, S.
    Saad, F.
    Li, T.
    Ito, T.
    Diels, J.
    Van Sanden, S.
    De Porre, P.
    Roiz, J.
    Abogunrin, S.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [38] Comparative analysis of gut microbiota in hormone-sensitive and castration-resistant prostate cancer in Japanese men
    Fujimoto, Saizo
    Hatano, Koji
    Banno, Eri
    Motooka, Daisuke
    De Velasco, Marco Antonio
    Kura, Yurie
    Toyoda, Shingo
    Hashimoto, Mamoru
    Adomi, Shogo
    Minami, Takafumi
    Yoshimura, Kazuhiro
    Oka, Toshiki
    Hata, Junya
    Matsushita, Makoto
    Takao, Tetsuya
    Takada, Shingo
    Tsujimura, Akira
    Kojima, Yasuyuki
    Obara, Wataru
    Nakamura, Shota
    Uemura, Hirotsugu
    Nonomura, Norio
    Fujita, Kazutoshi
    CANCER SCIENCE, 2024,
  • [39] Clinicopathological predictors of favourable response to docetaxel in patients with metastatic castration-resistant prostate cancer
    Bentick, G.
    Balasubramanian, A.
    Anton, A.
    Azad, A.
    Brown, S.
    Goh, J. C. H.
    Wong, S. S. L.
    Parente, P.
    Shapiro, J.
    Liow, E. C. H.
    Torres, J.
    Smith, A.
    Steer, C.
    Warren, M.
    Gibbs, P.
    Tran, B.
    Weickhardt, A. J.
    ANNALS OF ONCOLOGY, 2024, 35
  • [40] Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
    Kreis, Kristine
    Horenkamp-Sonntag, Dirk
    Schneider, Udo
    Zeidler, Jan
    Glaeske, Gerd
    Weissbach, Lothar
    BJU INTERNATIONAL, 2022, 129 (04) : 470 - 479
12345